Xeris Pharmaceuticals has been granted a patent allowance for its product, Keveyis, which is now protected until the year 2039. This patent will secure the company's intellectual property rights and exclusivity in the market for this particular medication. The allowance is a significant milestone for Xeris, as it reinforces the company's commitment to advancing its therapeutic offerings.
Related Articles
Don't miss out on breaking stories and in-depth articles.